XenoPort Reviews

11 Reviews
Rating Trends
Recommend to a friend
Approve of CEO
XenoPort CEO and Director Ron Barrett
Ron Barrett
8 Ratings
  • Used to be a nice place to work

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Career Opportunities
    Former Employee - Anonymous Employee in Santa Clara, CA
    Former Employee - Anonymous Employee in Santa Clara, CA

    I worked at XenoPort


    Ron is a great guy and a strong leader. He needs to keep focused on moving drug candidates forward and earn FDA approval


    There is no current on going research program. Therefore, the long term potential for the success of this company is unknown.

    Advice to ManagementAdvice

    Please remember to value your employees, and do not lose focus of their contributions. Encourage communication within and across all departments.

    Approves of CEO

XenoPort Interviews

Interview Experience

Interview Experience


Getting an Interview

Getting an Interview


Interview Difficulty


Interview Difficulty




    Senior Scientist Interview

    Anonymous Interview Candidate
    Anonymous Interview Candidate
    Application Details

    I applied through a recruiter. The process took a dayinterviewed at XenoPort in May 2008.

    Interview Details

    very ggod and straightforward

    Interview Questions
    • if this is the question, how will you address it   View Answer
    Accepted Offer
    Positive Experience
    Easy Interview

XenoPort Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.xenoport.com
Headquarters Santa Clara, CA
Size 50 to 149 Employees
Founded 1999
Type Company - Public (XNPT)
Industry Biotech & Pharmaceuticals
Revenue $5 to $10 million (USD) per year

XenoPort sounds like something straight out of science fiction, but there's nothing fictional about XenoPort's job of improving drugs' ability to be absorbed by tissues in the body. The development firm uses genomics to identify transporter proteins. It then designs oral drug molecules to find and ride these transporters through the gastrointestinal tract to their destination. XenoPort began marketing its first drug in 2011 when it received FDA approval for its gabapentin enacarbil candidate, Horizant, to treat restless legs syndrome (RLS). XenoPort markets Horizant in the... More

Work at XenoPort? Share Your Experiences


Click to Rate